5 completed. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 1 | Completed 1 |
Follow crenolanib: new trials by email Literature Review of crenolanib trials Research Report on crenolanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma Crenolanib, Ramucirumab, Paclitaxel - Esophagogastric Adenocarcinoma | Phase 1 | Completed | Arog Pharmaceuticals, Inc. | 30 | 2017-04-14 | 2020-07-20 |
| Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML Crenolanib, Mitoxantrone, Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Completed | Arog Pharmaceuticals, Inc. | 16 | 2016-02-01 | 2023-12-20 |
| Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Crenolanib, Sorafenib, methotrexate, hydrocortisone and cytarabine with leucovorin - Acute Myeloid Leukemia | Phase 1 | Completed | St. Jude Children's Research Hospital | 10 | 2015-04-02 | 2017-10-03 |
| PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Crenolanib - Diffuse Intrinsic Pontine Glioma, Progressive or Refractory High-Grade Glioma | Phase 1 | Completed | St. Jude Children's Research Hospital | 55 | 2011-07-01 | 2017-04-26 |
| CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors CP-868,596, Docetaxel, AG-013736 - Advanced Solid Tumors | Phase 1 | Completed | Arog Pharmaceuticals, Inc. | 50 | 2005-12-01 | 2012-01-19 |
Leukemia, Myeloid, Acute (2) · Diffuse Intrinsic Pontine Glioma (1) · Glioma (1)
Arog Pharmaceuticals, Inc. (3) · St. Jude Children's Research Hospital (2)
United States (5) · Australia (1)
Alberto Broniscer, MD (1) · Geoffrey Ku, MD (1) · Hiroto Inaba, MD, PhD (1)